GET DAILY SIGNALSChemomab Therapeutics (CMMB): What to Watch Ahead of Q3 2026 Earnings
Key Takeaways
- Chemomab Therapeutics (CMMB) is expected to report its third-quarter 2026 results in early November 2026 (estimated for November 6, before the market opens), with a narrow consensus earnings estimate of roughly -$0.01 per share.
- As a clinical-stage biotechnology company, Chemomab generates no product revenue, so investors will focus on operating expenses, net loss, and cash burn rather than top-line sales.
- Cash, cash equivalents, and short-term bank deposits totaled $6.7 million as of June 30, 2026, and management has guided that current liquidity can fund operations through the first quarter of 2027.
- Updates on nebokitug (CM-101), the company's lead antibody targeting the CCL24 protein for primary sclerosing cholangitis (PSC, a rare, progressive liver disease), will be central, including any progress toward a Phase 3 trial.
- Research and development (R&D) expenses have declined as the Phase 2 SPRING trial wound down, falling to $1.1 million in Q2 2026 from $1.3 million a year earlier.
- For more context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- You can also explore Trending AI Robots to see how AI-driven strategies are navigating current market conditions.
Why This Earnings Report Matters
For a pre-revenue biotech like Chemomab Therapeutics (CMMB), a quarterly earnings release is less about sales growth and more about two questions: how quickly is the company spending its cash, and how far along is its lead drug candidate. The company's lead program, nebokitug (CM-101), targets CCL24, a protein implicated in fibrosis and inflammation, with a lead indication in primary sclerosing cholangitis (PSC), a rare liver disease with no approved therapies. Positive Phase 2 SPRING trial results were published in the American Journal of Gastroenterology in late 2025, and management is preparing for a potential Phase 3 trial. With a modest cash balance and a runway extending only into early 2027, this report will clarify spending trends and the company's funding strategy heading into a pivotal development stage. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Modeling
Consensus estimates point to a roughly break-even quarter, with analysts modeling earnings of approximately -$0.01 per share for Q3 2026, and no revenue expectations given the company's clinical-stage status. In its most recent reported quarter (Q2 2026, released August 19, 2026), Chemomab posted a net loss of $2.2 million. R&D expenses were $1.1 million and general and administrative (G&A) expenses were $1.1 million, reflecting a leaner cost structure as the SPRING trial concluded.
Cash, cash equivalents, and short-term deposits stood at $6.7 million as of June 30, 2026, down from $8.0 million at the end of March 2026. Management has stated that existing liquidity should fund operations through the first quarter of 2027. Because the company reports results in both ordinary shares and American Depositary Shares (ADSs, with one ADS representing 80 ordinary shares), per-share figures can vary across data providers; investors should note the basis used when comparing figures to consensus estimates.
Market Reaction and Sentiment
Sentiment heading into this report is shaped by the company's thin cash position and the timing of its next development milestone. Chemomab's stock has been volatile, and with a limited number of analysts covering the name, consensus expectations are narrow. Historically, the company's EPS results have missed consensus estimates in several recent quarters, partly due to differing per-share reporting conventions between ordinary shares and ADSs. The key risks heading into earnings include the pace of cash burn, the potential for dilutive financing, and any delays or changes to the Phase 3 trial timeline for nebokitug. Investors will be listening closely to management commentary on funding strategy and regulatory progress, which are likely to drive a larger reaction than the headline net loss figure itself.
Looking Ahead: Key Items to Follow
Looking beyond the Q3 print, the central question is how Chemomab finances the next phase of nebokitug's development. The company has guided a cash runway only through the first quarter of 2027, which means capital-raising activity — whether through equity offerings, partnerships, or other arrangements — is a near-term consideration that could affect the share count and investor positioning.
On the clinical side, investors should monitor the design and initiation timeline for a Phase 3 trial in primary sclerosing cholangitis. Management has indicated the Phase 3 design calls for a single pivotal trial with a clinical event primary endpoint, a streamlined path it believes could support full regulatory approval. Nebokitug has already received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA), which may facilitate interactions with regulators.
Finally, watch for any updates on the broader nebokitug program, including the systemic sclerosis indication, and for scientific presentations or publications that could reinforce the biomarker data from the SPRING trial. Each of these factors could reshape the risk-reward profile around Chemomab's upcoming earnings and its path toward late-stage development.
Using AI Tools in My Research
In my own work, I frequently rely on Tickeron’s AI Screener to quickly filter biotechnology names by fundamentals, volatility, and recent patterns. It allows me to compare CMMB against peers and spot any unusual trading activity ahead of events like earnings. The tool has become a regular part of how I prepare for these types of updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CMMB turns negative, indicating new downward trend
CMMB saw its Momentum Indicator move below the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned negative. In 69 of the 74 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
CMMB moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CMMB crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CMMB entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CMMB's RSI Oscillator exited the oversold zone, 33 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CMMB just turned positive on October 27, 2026. Looking at past instances where CMMB's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +10.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMMB advanced for three days, in 195 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CMMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.928) is normal, around the industry mean (3.151). P/E Ratio (-1.146) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. CMMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services
Industry Biotechnology
Advertisement